Virtual Meetings 2018

Virtual Molecular Tumor Board – A Webcast Series Exploring the Role of Molecular Profiling in Metastatic Breast Cancer

We are pleased to offer medical oncologists throughout the United States the opportunity to participate in a pilot CME program on the role of tissue biomarkers in the management of metastatic breast cancer. Participants will join us virtually from the comfort of their own homes or offices using video conferencing technology as we partner with the Indiana University School of Medicine to discuss challenging cases for which biomarker analysis may inform treatment decision-making.

For each virtual event, participating clinicians will be encouraged to present cases to the multidisciplinary faculty panel from Indiana University. If you wish to participate in one or multiple sessions and have a case on which you would like input, please email a brief write-up and any questions that you have to DrNeilLove@ResearchToPractice.com prior to the tumor board(s) that you wish to attend and click on the link below to preregister.

Faculty:
Bryan P Schneider, MD
Indiana University Melvin and
Bren Simon Cancer Center
Indianapolis, Indiana

Milan Radovich, PhD
Indiana University Melvin and
Bren Simon Cancer Center
Indianapolis, Indiana

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Schedule of Events
All sessions will take place from 1:00 PM - 2:00 PM ET.
To register for any of the events or to learn more, click on the corresponding link below.

Virtual Session III: Estrogen Receptor and HER2 Tumor Mutations
Tuesday, March 6, 2018
Virtual Session IV: Androgen Receptor Assays and Antiandrogen Therapy
Tuesday, March 20, 2018
Virtual Session V: Immune Checkpoint Inhibitors and Predictors of Response
Tuesday, April 3, 2018

Previous Event

Virtual Session I: Multiplex Tumor Assays and Next-Generation Sequencing
Held on January 23, 2018
Virtual Session II: BRCA and BRCA-Like Germline and Somatic Mutations and Use of PARP Inhibitors
Held on February 6, 2018

These events are free of charge.

Target Audience:
These activities are intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives:
At the conclusion of each activity, participants should be able to:

  • Multiplex Tumor Assays and Next-Generation Sequencing:
    • Appreciate patient- and disease-specific factors in managing metastatic breast cancer, and consider the potential role of emerging information on novel molecular targets in formulating treatment plans.
    • Develop an approach to testing and interpreting results to optimize personalized treatment recommendations.
    • Appraise the role of multiplex/next-generation sequencing in informing treatment decision-making for patients with metastatic breast cancer, including participation in clinical trials of targeted therapy.
  • BRCA and BRCA-Like Germline and Somatic Mutations and Use of PARP Inhibitors:
    • Appreciate patient- and disease-specific factors in managing metastatic breast cancer (mBC), and consider the potential role of emerging information on novel molecular targets in formulating treatment plans.
    • Develop an approach to testing and interpreting results to optimize personalized treatment recommendations.
    • Appreciate the recent FDA approval of olaparib in patients with germline BRCA-mutated, HER2-negative mBC, and formulate an approach to BRCA testing of patients with breast cancer that considers the approved companion diagnostic.
CME Credit Form:
A CME credit form will be given to each participant at the conclusion of each activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of each CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.